Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

Chang Yu Chen, Yung Song Lin, Chien Ho Chen, Yin Ju Chen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Nasopharyngeal carcinoma (NPC) is a head and neck cancer with poor clinical outcomes and insufficient treatments in Southeast Asian populations. Although concurrent chemoradiotherapy has improved recovery rates of patients, poor overall survival and low efficacy are still critical problems. To improve the therapeutic efficacy, we focused on a tumor-associated protein called Annexin A2 (ANXA2). This review summarizes the mechanisms by which ANXA2 promotes cancer progression (e.g., proliferation, migration, the epithelial-mesenchymal transition, invasion, and cancer stem cell formation) and therapeutic resistance (e.g., radiotherapy, chemotherapy, and immunotherapy). These mechanisms gave us a deeper understanding of the molecular aspects of cancer progression, and further provided us with a great opportunity to overcome therapeutic resistance of NPC and other cancers with high ANXA2 expression by developing this prospective ANXA2-targeted therapy.

Original languageEnglish
Article number30
JournalJournal of Biomedical Science
Volume25
Issue number1
DOIs
Publication statusPublished - Mar 29 2018

Fingerprint

Annexin A2
Annexins
Chemoradiotherapy
Neoplasms
Chemotherapy
Radiotherapy
Stem cells
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Tumors
Therapeutics
Head and Neck Neoplasms
Immunotherapy
Recovery
Drug Therapy
Survival
Nasopharyngeal carcinoma
Proteins
Population

Keywords

  • Annexin A2 (ANXA2)
  • Cancer progression
  • Nasopharyngeal carcinoma (NPC)
  • Therapeutic resistance

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma. / Chen, Chang Yu; Lin, Yung Song; Chen, Chien Ho; Chen, Yin Ju.

In: Journal of Biomedical Science, Vol. 25, No. 1, 30, 29.03.2018.

Research output: Contribution to journalArticle

@article{9ceb074be6be46d58008e85b525fe58d,
title = "Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma",
abstract = "Nasopharyngeal carcinoma (NPC) is a head and neck cancer with poor clinical outcomes and insufficient treatments in Southeast Asian populations. Although concurrent chemoradiotherapy has improved recovery rates of patients, poor overall survival and low efficacy are still critical problems. To improve the therapeutic efficacy, we focused on a tumor-associated protein called Annexin A2 (ANXA2). This review summarizes the mechanisms by which ANXA2 promotes cancer progression (e.g., proliferation, migration, the epithelial-mesenchymal transition, invasion, and cancer stem cell formation) and therapeutic resistance (e.g., radiotherapy, chemotherapy, and immunotherapy). These mechanisms gave us a deeper understanding of the molecular aspects of cancer progression, and further provided us with a great opportunity to overcome therapeutic resistance of NPC and other cancers with high ANXA2 expression by developing this prospective ANXA2-targeted therapy.",
keywords = "Annexin A2 (ANXA2), Cancer progression, Nasopharyngeal carcinoma (NPC), Therapeutic resistance",
author = "Chen, {Chang Yu} and Lin, {Yung Song} and Chen, {Chien Ho} and Chen, {Yin Ju}",
year = "2018",
month = "3",
day = "29",
doi = "10.1186/s12929-018-0430-8",
language = "English",
volume = "25",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

AU - Chen, Chang Yu

AU - Lin, Yung Song

AU - Chen, Chien Ho

AU - Chen, Yin Ju

PY - 2018/3/29

Y1 - 2018/3/29

N2 - Nasopharyngeal carcinoma (NPC) is a head and neck cancer with poor clinical outcomes and insufficient treatments in Southeast Asian populations. Although concurrent chemoradiotherapy has improved recovery rates of patients, poor overall survival and low efficacy are still critical problems. To improve the therapeutic efficacy, we focused on a tumor-associated protein called Annexin A2 (ANXA2). This review summarizes the mechanisms by which ANXA2 promotes cancer progression (e.g., proliferation, migration, the epithelial-mesenchymal transition, invasion, and cancer stem cell formation) and therapeutic resistance (e.g., radiotherapy, chemotherapy, and immunotherapy). These mechanisms gave us a deeper understanding of the molecular aspects of cancer progression, and further provided us with a great opportunity to overcome therapeutic resistance of NPC and other cancers with high ANXA2 expression by developing this prospective ANXA2-targeted therapy.

AB - Nasopharyngeal carcinoma (NPC) is a head and neck cancer with poor clinical outcomes and insufficient treatments in Southeast Asian populations. Although concurrent chemoradiotherapy has improved recovery rates of patients, poor overall survival and low efficacy are still critical problems. To improve the therapeutic efficacy, we focused on a tumor-associated protein called Annexin A2 (ANXA2). This review summarizes the mechanisms by which ANXA2 promotes cancer progression (e.g., proliferation, migration, the epithelial-mesenchymal transition, invasion, and cancer stem cell formation) and therapeutic resistance (e.g., radiotherapy, chemotherapy, and immunotherapy). These mechanisms gave us a deeper understanding of the molecular aspects of cancer progression, and further provided us with a great opportunity to overcome therapeutic resistance of NPC and other cancers with high ANXA2 expression by developing this prospective ANXA2-targeted therapy.

KW - Annexin A2 (ANXA2)

KW - Cancer progression

KW - Nasopharyngeal carcinoma (NPC)

KW - Therapeutic resistance

UR - http://www.scopus.com/inward/record.url?scp=85044616204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044616204&partnerID=8YFLogxK

U2 - 10.1186/s12929-018-0430-8

DO - 10.1186/s12929-018-0430-8

M3 - Article

VL - 25

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 30

ER -